RELATIONSHIP BETWEEN BENIGN PROSTATIC HYPERPLASIA AND CORONARY ARTERY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Introduction: The prevalence of Benign Prostate Hyperplasia (BPH) increased to 40% in men over 40 and then to about 80% in men over 70. Prior research has demonstrated a correlation between inflammatory processes in the development of Benign Prostatic Enlargement (BPE), Lower Urinary Tract Syndrome (LUTS), and coronary artery disease (CAD) and symptoms of atherosclerotic illness, such as dyslipidemia, hypertension, and non-insulin-dependent diabetic mellitus. Objective: In this study, we would like to review studies regarding the relationship between BPH and CAD. Material & Methods: This study was a combination of systematic review followed by a meta-regression analysis. Performed on PubMed and Google Scholar. Randomized controlled trials, prospective and retrospective cohort studies were included in the study. The search was performed in English and was limited to articles published between January 1st, 2000 until October 31st, 2023. Results: Database search yielded a total of 103 articles, which were systematically eliminated, leaving 7 relevant articles. Analyzed articles showed a significant relationship between BPH and CAD. CAD was proven to be significantly able to provide a higher risk on BPH by 2.99 times compared to control. Conclusion: Compared to individuals without BPH, there was a substantial correlation between CAD and BPH patients. Keywords: Benign prostate hyperplasia, coronary artery disease, lower-urinary tract syndrome, systemic review.
##plugins.themes.bootstrap3.article.details##
benign prostate hyperplasia, coronary artery disease, lower urinary tract syndrome, systemic review
Wang X, Su Y, Yang C, Hu Y, Dong JY. Benign prostatic hyperplasia and cardiovascular risk: a prospective study among Chinese men. World Journal of Urology. 2022;40(1):177–83.
Berger AP, Bartsch G, Deibl M, Alber H, Pachinger O, Fritsche G, et al. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU International. 2006;98(5):1038–42.
Berger AP, Deibl M, Halpern EJ, Lechleitner M, Bektic J, Horninger W, et al. Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia. Diabetologia. 2005;48:784–9.
Chughtai B, Simma-Chiang V, Kaplan SA. Evaluation and management of post-transurethral resection of the prostate lower urinary tract symptoms. Current urology reports. 2014 Sep;15(9):434.
Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). International Journal of Obesity. 2005;29(3):310–6.
Madjid M, Willerson JT. Inflammatory markers in coronary heart disease. British medical bulletin. 2011;100(1).
Güven EO, Selvi I, Karaismailoğlu E. Association between benign prostate enlargement-related storage and voiding symptoms and systolic blood pressure: a single-center cross-sectional study. Sao Paulo Medical Journal. 2020;137:446–53.
Russo GI, Castelli T, Privitera S, Fragalà E, Favilla V, Reale G, et al. Increase of Framingham cardiovascular disease risk score is associated with severity of lower urinary tract symptoms. BJU International. 2015;116(5):791–6.
Meigs JB, Mohr B, Barry MJ, Collins MMN, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. Journal of Clinical Epidemiology. 2001;54(9):935–44.
Inci M, Baydilli N, Akçay AB, Demirtaş A, Rifaioʇlu MM, Gözükara KH, et al. The investigation of relationship between coronary artery ectasia, benign prostatic enlargement, and lower urinary tract symptoms. Urology. 2015;85(6):1436–40.
Weisman KM, Larijani GE, Goldstein MR, Goldberg ME. Relationship between benign prostatic hyperplasia and history of coronary artery disease in elderly men. Pharmacotherapy. 2000;20(4):383–6.
Sharma RS. Correlation between Benign Prostatic Hyperplasia and Coronary Artery Disease. International Journal of Scientific Study. 2017;5(5):191–6.
Bouwman II, Blanker MH, Schouten BW V, Bohnen AM, Nijman RJM, van der Heide WK, et al. Are lower urinary tract symptoms associated with cardiovascular disease in the Dutch general population? Results from the Krimpen study. World journal of urology. 2015;33:669–76.
Platz EA, Kawachi I, Rimm EB, Colditz GA, Stampfer MJ, Willett WC, et al. Physical activity and benign prostatic hyperplasia. Archives of internal medicine. 1998;158(21):2349–56.
Hammarsten J, Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. European urology. 2001;39(2):151–8.
Michel MC, MEHLBURGER L, SCHUMACHER H, BRESSEL HU, GOEPEL M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. The Journal of urology. 2000;163(6):1725–9.
Zimarino M, Cappelletti L, Venarucci V, Gallina S, Scarpignato M, Acciai N, et al. Age-dependence of risk factors for carotid stenosis: an observational study among candidates for coronary arteriography. Atherosclerosis. 2001;159(1):165–73.
Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes/metabolism research and reviews. 2006;22(6):423–36.
Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. European urology. 2007;51(1):199–206.
Harris AL. Hypoxia — a key regulatory factor in tumour growth. Nature Reviews Cancer. 2002;2(1):38–47.
Bagatell CJ, Bremner WJ. Androgen and progestagen effects on plasma lipids. Progress in cardiovascular diseases. 1995;38(3):255–71.
Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S, Maggi M. Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. International journal of endocrinology. 2014;2014.